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ABSTRACT:
Introduction:  Respiratory syncytial virus (RSV) is the leading viral
cause of acute lower respiratory infections globally, accounting for
high morbidity and mortality burden among children aged less
than 5 years. As candidate RSV vaccine trials in pregnant women
and infants are underway a greater understanding of RSV
epidemiology is now needed, especially in paediatric populations
with high rates of acute and chronic respiratory disease. The
objective was to identify RSV prevalence in children living in
northern Australia, a region with a high respiratory disease
burden.  
Methods:  Data were sourced from 11 prospective studies (four
hospital and seven community-based) of infants and children with
acute and chronic respiratory illnesses, as well as otitis media,
conducted between 1996 and 2017 inclusive. The data from
northern Australian children in these trials were extracted and,
where available and consented, their nasopharyngeal swabs
(biobanked at –80ºC) were tested by polymerase chain reaction
assays for RSV-A and B, 16 other viruses and atypical respiratory
bacterial pathogens.  
Results:  Overall, 1127 children were included. Their median age
was 1.8 years (interquartile range 0.5–4.9); 58% were male and 90%
Indigenous, with 81% from remote communities. After human
rhinoviruses (HRV), RSV was the second most prevalent virus (15%,
95% confidence interval (CI) 13–18). RSV prevalence was greatest
amongst children aged less than 2 years hospitalised with
bronchiolitis (47%, 95%CI 41.4–52.4), with more than two-thirds
with RSV aged less than 6 months. In contrast, the prevalence of
RSV was only 1–3.5% in other age groups and settings. In one-
third of RSV cases, another respiratory virus was also detected.
Individual viruses other than RSV and HRV were uncommon
(0–9%).
Conclusion:  Combined data from 11 hospital and community-
based studies of children aged less than 18 years who lived in
communities with a high burden of acute and chronic respiratory
illness showed that RSV was second only to HRV as the most
prevalent virus detected across all settings. RSV was the most
frequently detected virus in infants hospitalised with bronchiolitis,
including those aged less than 6 months. In contrast, RSV was
uncommonly detected in children in community settings. In
northern Australia, effective maternal and infant RSV vaccines
could substantially reduce RSV bronchiolitis-related
hospitalisations, including admissions of Indigenous infants from
remote communities.
Keywords:
Australia, children, hospitalisation, morbidity, respiratory, respiratory syncytial virus.
FULL ARTICLE:
Introduction
Respiratory syncytial virus (RSV) is a leading cause of acute lower
respiratory infections (ALRIs) in infants and young children (aged
<5 years) and in older people, accounting for a high burden of
morbidity and mortality . In infants and young children, RSV-
related ALRIs in young children are primarily bronchiolitis and
pneumonia . Globally, the impact of RSV is large, accounting for
33 million ALRI episodes, 3.2 million hospitalisations and 59 600
in-hospital deaths in those aged less than 5 years . Nevertheless,
these data likely underestimate the true disease burden as they do
not account for RSV ALRIs in older children , diagnostic
misclassification from hospital-based coding practices , and out-
of-hospital RSV-attributable deaths in low- and middle-income
countries . To reduce RSV disease in young children, several
candidate vaccines are currently undergoing development and
clinical trials . In preparation for introducing RSV vaccines, better
epidemiological data on RSV are needed, including clinic
attendance for ALRIs and data relevant to high-risk populations,
such as Indigenous children .
In Australia, Indigenous children have a high ALRI burden , with
hospitalisation rates as high as 427 per 1000 in Indigenous infants
from the Northern Territory (NT) . Indigenous children, especially
from remote communities, are seven times more likely to be
hospitalised with pneumonia than non-Indigenous
children . Moreover, hospitalised and recurrent ALRIs in the first
few years of life are associated with an increased risk of future
impaired lung health , reduced lung function  and
bronchiectasis . Indeed, the authors’ previous work among
young children aged less than 24 months hospitalised with
bronchiolitis showed that Indigenous children have more severe
disease (eg longer duration of hospitalisation and supplemental
oxygen requirement)  and poorer clinical outcomes post-
hospitalisation (re-hospitalisation for respiratory illnesses within
6 months) than non-Indigenous children . Moreover,
Indigenous children with prolonged cough 3–4 weeks after
hospitalisation for bronchiolitis were at increased risk of future
bronchiectasis (odds ratio (OR) 3.0, 95% confidence interval (CI)
1.1–7.0, p=0.03) .
RSV is the commonest cause of hospitalised ALRIs in Australian
children . National as well as population-based data-linkage
studies from the states of Western Australia and New South Wales
found RSV hospitalisation incidence rates approximately two-to-
four times higher in Indigenous than non-Indigenous
children . Similar disparities in RSV-related ALRIs between
Indigenous and non-Indigenous children are reported in hospital-
based studies from central Australia  and the top end of the NT .
However, while community-based studies of RSV–ALRI are needed
to capture the full spectrum of severity and for cost-effective
analyses of future vaccines, few exist in Australia .
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In addition to the limited community-based data on RSV
prevalence among Indigenous children in the northern Australian
setting, data relating to co-detection of other viruses with RSV in
this population are also scarce. Nevertheless, the clinical relevance
of single versus multiple virus detections in ALRIs remains unclear,
especially as 23–55% of virus detection in community-based
surveillance studies are unaccompanied by any symptoms .
To begin addressing this knowledge gap, the authors of this study
determined the point prevalence of RSV in northern Australian
children by conducting a secondary analysis of 11 hospital and
community-based studies of children with ALRIs (principally
bronchiolitis), otitis media and chronic pulmonary disorders, which
included investigations during periods without acute respiratory
illness and involved mainly Indigenous participants . The
secondary aim was to describe the prevalence of RSV co-
detections with other respiratory viruses.
Methods
Study design and settings
Data were sourced from 11 prospective studies (Table 1). Eight
involved children with either acute or chronic respiratory
illnesses , one involved children who acted as case-
controls in study 4 and the remaining two focused on otitis
media . These were conducted in the NT, central Australia, and in
the northern Queensland city of Townsville between 1996 and
2017 inclusive. One of the studies is ongoing, and the main results
(reporting of primary aims) of seven studies and a substudy have
been published already .
Hospital-based studies included the Royal Darwin Hospital and
Alice Springs Hospital in the NT, and the Townsville Hospital in
Queensland. The Royal Darwin , Alice Springs  and Townsville
hospitals  are 360-, 186- and 580-bed teaching hospitals
respectively with each containing the sole specialist paediatric
services for their regions (Fig1). Community-based studies were
undertaken across the NT, including central Australia, and in
Queensland (communities vary according to the original studies,
Table 1).
For each study, data custodians provided written approval for data
to be accessed. Each original study received ethics approval with
informed consent obtained for all nasopharyngeal swabs (NPSs)
opting in to approve future analyses.
Table 1:  Description of studies, clinical state and setting
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Figure 1:  Hospital catchment areas.
Geographical region and climate
The NT consists of two main regions: the tropical north and central
Australia. The tropical north has two distinct seasons: the dry (May
to October) and wet (November to April) seasons. Central Australia
(including the Anangu Pitjantjatjara Yankunytjatjara Lands, of
northern South Australia) is a semi-desert region that has a typical
four-season pattern. Townsville is a coastal city situated in north-
eastern Queensland, with a tropical climate similar to the NT
tropical north.
Study population
Children aged less than 18 years with recorded NPS virus results,
or stored NPS specimens available, and consented for future
testing, were eligible for inclusion. No other inclusion criteria were
used, as eligibility criteria varied between each of the original
studies (Supplementary table 1).
Supplementary table 1:  Summary of included studies
Clinical data
A hierarchical approach was used to identify data from the original
studies. For acute hospital or community-based studies
where more than one clinical visit was recorded and children were
either hospitalised or treated at the local health centre, ALRIs were
defined according to previous clinical trials . This was age-
adjusted tachypnoea with wheeze or crackles in otherwise
previously well infants and young children with bronchiolitis ,
and any combination of increased cough, dyspnoea, increased
sputum volume or purulence, haemoptysis, or new chest
examination or radiographic findings in children with known
chronic suppurative lung disease or bronchiectasis . For non-
acute studies , the authors selected the first available healthy
visit (ie no acute respiratory illness) with available virus testing
data. For the otitis media-related studies , the authors selected
the first clinical visit where virus testing results were available.
Data custodians extracted de-identified data using a pre-specified
list of variables (as available), including age, ethnicity, birth history,
breastfeeding, family history, exposure to tobacco (during
pregnancy and in the household), chronic pulmonary disorders,
other co-existing illnesses (eg pyoderma, otitis media, rheumatic
heart disease, faltering growth), setting (hospital/community),
viruses, season (dry/wet season in the tropics of the NT and
Queensland) and region (urban/remote). As per the authors’
previous studies, remoteness was defined as more than 100 km
from a tertiary hospital . Before merging data sets,
variables were recoded to ensure identical coding between studies.
Virus data
In all studies, an NPS was collected and placed into skim milk
tryptone glucose glycerol broth (STGGB), and stored at –80°C
using standardised procedures at the Menzies School of Health
Research . Where virus result data were not already available, an
aliquot of the stored STGGB was submitted by courier to the
Queensland Paediatric Infectious Diseases laboratory in Brisbane,
which had acted as the reference laboratory for all studies. The
polymerase chain reaction assays used have been reported
previously  and included testing for RSV (A and B), HRV,
human adenovirus, parainfluenza (1, 2, 3), influenza virus (A and B),
human metapneumovirus, human enterovirus, human
coronaviruses (NL63, OC43, 229E, HKU1), human bocavirus and
human polyomaviruses (KI, WU).
Statistical analysis
Descriptive analyses were conducted using Stata v14 (StataCorp;
http://stata.com). As data were not normally distributed, non-
parametric measures were used. Patient characteristics are
presented as numbers and percentages, median and interquartile
ranges (IQR: 25th – 75th percentile). As this was an opportunistic
study of available data, sample size calculation was not
undertaken.
Ethics approval
The Human Research Ethics Committee of the NT Department of
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Health and Menzies School of Health Research approved the
current study (HREC-17-3025).
Results
The demographic and clinical data for the 1127 children included
in this study are summarised in Table 2. More children were from
hospital studies (n=621) than community-based studies (n=506).
The median age of children was 1.8 years (IQR 0.5–4.9); 58% were
males, 90% were Indigenous, of whom 81% were from remote
communities, and 57% had at least one co-existing illness.
Exposure to tobacco smoke varied between studies and settings;
however overall, it was very high during pregnancy (54%) and at
home (73%). Overall, 77% of NPS collected from children during
‘well child’ (ie non-acute respiratory) visits and otitis media studies
were conducted during the dry season, due to lack of accessibility
to remote communities at other times of the year.
Table 2:  Baseline characteristics by setting and condition
Prevalence of respiratory syncytial virus by setting, study type
and condition
The overall point prevalence of RSV was 173/1127 or 15% (95%CI
13–18). RSV grouped by setting and condition are summarised in
Table 3. The point prevalence of RSV was highest in hospital-based
studies of bronchiolitis in children aged less than 24 months
(156/333; 47%, 95%CI 41–52) and of these 107/156 (69%) were
infants aged less than 6 months (95%CI 61–76). In contrast, RSV
was detected in only 2.1% (17/794, 95%CI 1.3–3.4) of children
across other clinical settings. This included children who were
clinically stable and undergoing an elective bronchoscopy for
chronic respiratory symptoms (study 9). In community-based
studies of otitis media (studies 10 and 11), those undergoing a
‘well child’ outpatient review after hospitalisation for bronchiolitis
or who were part of the case-control study (studies 6 and 7), and
children with non-severe (non-hospitalised), acute pulmonary
exacerbations of chronic suppurative lung disease or
bronchiectasis (studies 4, 5 and 8), the prevalence of RSV was 1.4%
(7/506, 95%CI 0.6–2.8).
Table 3:  Prevalence of respiratory syncytial virus by setting and condition 
Other viruses, including RSV co-detections
Detection of other respiratory viruses in NPS samples varied
according to setting and type of illness (Table 4). HRV was the virus
detected most commonly in community-based studies, with
highest detections in otitis media (prevalence 57%, 95%CI 47–67).
The prevalence range for other viruses was 0–9%. At least one virus
was detected in 706 (63%, 95%CI 59–68) children with 227 (20%,
95%CI 18–23) having two or more viruses present. Of the 173 RSV
detections, 56 (33%, 95%CI 26–40) involved co-detection with
other viruses and where HRV co-detection was the most
common (27/173, 16%).
Table 4:  Distribution of respiratory viruses and atypical bacterial pathogens by setting and condition
Discussion
This study provides RSV prevalence data for northern Australia
derived from 11 prospective hospital- and community-based
studies involving 1127 subjects in a setting where children are at
high risk of acute and chronic respiratory illnesses . While
limited, it begins to address recommendations made by WHO to
gather more information on local RSV epidemiology and disease
burden in disadvantaged populations while awaiting future
licensed RSV vaccines . It was found that RSV was second only to
HRV with an overall prevalence of 15% in the study region. RSV
point prevalence of 47% was highest in children aged less than
24 months hospitalised with bronchiolitis, whereas prevalence in
community-based studies was only 1.4% in children with either
otitis media or in older children aged up to 18 years with or
without ALRI respiratory symptoms. In contrast, HRV was common
across all clinical settings and ages, including having a point
prevalence of 30% in clinically stable children without either ALRI
symptoms or otitis media. Finding HRV in asymptomatic children is
not surprising as reported in several other studies, such as that
described by Advani et al, where HRV was detected in near-equal
numbers in hospitalised children with respiratory symptoms
(41/148, 27.7%) and those without (34/158, 21.5%) . Viruses other
than RSV and HRV were uncommon, with point prevalence rates
less than 10%. Co-detection of RSV with other respiratory viruses
was 33% across all clinical settings.
The present study data are consistent with other hospital-based
ALRI studies that also include Indigenous infants with bronchiolitis,
where RSV was detected in 41–83% of patients . In the
present study, 31% of children hospitalised with RSV-related
bronchiolitis were aged 6–24 months, when maternal RSV
vaccination may no longer be protective, , emphasising the
importance of also developing active immunisation programs for
young infants. In contrast to hospital-based studies, detection of
RSV was low in the seven community-based studies (1.4% of
children overall; 2.2% in those with and 0.9% without an acute
respiratory illness).
It was not possible to calculate the population-based incidence of
RSV-ALRI in our studies. In the Australian state of New South
Wales, a data-linkage study determined RSV-hospitalisation
incidence at 4.9 (11.0 in Indigenous children) per 1000 child years
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in those aged less than 5 years (peak incidence at age 0–3 months
was 25.6 per 100 child years (58.0 in Indigenous children) .
Differences in the incidence of RSV is likely multi-factorial, and
influenced by age, disease states, timing (season) and duration of
surveillance . Without active surveillance in the study region, the
true incidence and disease burden of RSV are unknown, although a
higher incidence of RSV-related ALRI in community studies is
expected, due to the high burden of respiratory disease among
Indigenous people compared to non-Indigenous people . The
most likely reasons for lower-than-expected rates of RSV detection
in community studies include sampling from comparatively older
children, and lack of acute respiratory symptoms . Most of
these children were seen in the dry season (May to October),
rather than during the peak respiratory period in the wet season
(November to April) , and this is also likely be a contributing
factor to differences in RSV detection.
Co-detection of other viruses with RSV was relatively common,
occurring in one-third of cases. The most common co-detected
virus was HRV, followed by the DNA viruses, human polyomavirus
WU and adenovirus. The clinical relevance of virus co-detections in
children with an ALRI remains uncertain . In a recent community-
based birth cohort study of young Australian children, single
infections with RSV and human metapneumovirus were found to
be most strongly associated with symptomatic ALRI; this study
observed that new virus co-detections were also associated with a
significantly increased attributed risk of symptoms .
The present study has several limitations. No prospective
longitudinal studies of RSV in at-risk Indigenous children have
been reported in the study region. An Australian urban
community-based study of healthy infants followed prospectively
from birth to age 2 years  observed RSV infections were
uncommon until after age 6 months, following which there was a
steady increase in RSV detections. By age 2 years, 58% of the
cohort had at least one documented RSV infection. Similar findings
were reported in a birth cohort from semi-rural villages in
Vietnam  and in Kenya . Nevertheless, these studies may not
represent children in the study region who are at high risk of
severe ALRIs. This was an opportunistic secondary analysis of data
from studies not designed specifically for determining RSV
epidemiology. The data had limited seasonal coverage, thus not
fully capturing annual outbreaks of RSV. Ninety percent of children
were Indigenous, 81% of whom were from remote communities. A
prospective, community-based study of non-Indigenous children
in the region would be informative. A more comprehensive study
is indicated to more accurately identify risk factors for RSV
infection and priority target groups for future RSV vaccination.
Lastly, the authors were unable to report mortality as these data
were not collected.
Conclusion
This study combines hospital- and community-based studies of
children aged less than 18 years who live in settings with a high
burden of acute and chronic respiratory illness. The authors found
RSV was second only to HRV as the most prevalent virus detected
across all settings. RSV was the most frequently detected virus in
infants hospitalised with bronchiolitis, including those aged less
than 6 months. In contrast, RSV was uncommonly detected in
children in community settings. While other respiratory viruses
were often co-detected with RSV, their contribution to the child’s
clinical state is uncertain. Ongoing surveillance of RSV  in hospital
and community settings is needed to further understand its
epidemiology, particularly in at-risk populations (ie Indigenous)
within Australia to guide prevention strategies and future RSV
vaccine schedules. The young age of most RSV-positive
hospitalised cases suggests a potential benefit from future
maternal RSV vaccine programs.
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